VRTX VERTEX PHARMACEUTICALS INC / MA Insider Trading

CMO Carmen Bozic sells 4,062 shares of VRTX at $450.00 (scheduled 10b5-1 plan; held 21,015 pre-sale)

Carmen Bozic, EVP and CMO, sold 4,062 shares of Vertex Pharmaceuticals at $450.00 on 2026-06-15, representing 19.3% of her prior 21,015-share holdings, for a total transaction value of $1,827,900.00. This sale is part of a pre-arranged 10b5-1 trading plan, meaning the transaction was scheduled in advance rather than discretionary. At the current price of $458.99, Bozic retained 16,953 shares. Across her cross-ticker open-market history, Bozic's prior 19 sells averaged a -0.6% 30-day return and +4.8% 90-day return; at Vertex specifically, her five prior trades (all sells between 2026-03-27 and 2026-06-05) show mixed 30-day outcomes (-1.9% to -4.6%) with limited measurable 90-day data. The stock trades 9.6% below its 52-week high of $507.92 and has posted a 30-day gain of 5.1%, while the company reports strong fundamentals: $3.0B latest-quarter revenue, $1.0B net income, and 8.9% annual revenue growth.

VRTX EVP Carmen Bozic sold 1,745 shares at $450.00 on 2026-06-05 (10b5-1 plan)

Carmen Bozic sold 1,745 shares of VERTEX PHARMACEUTICALS INC / MA at $450.00 on 2026-06-05, reducing holdings from 22,760 to 21,015 shares. This transaction is part of a pre-arranged 10b5-1 trading plan and therefore scheduled, not discretionary. Historically at VRTX, Bozic's five prior sales have been followed by negative 30-day and 90-day returns: -3.3%, -2.6%, -4.6%, -9.4%, and -9.8% on the 30-day basis, with 90-day returns of -3.3%, -2.6%, -2.8%, -9.0%, and -6.7% respectively. The current stock price of $445.77 is -12.2% from the 52-week high of $507.92, though it has gained +3.7% over the past 30 days. With the company posting $1.0B net income on $3.0B quarterly revenue and an 8.9% annual revenue growth rate, the fundamentals remain solid at a 26.08 P/E ratio.

EVP/CMO Carmen Bozic sold 1,974 shares of VRTX at $450.00 via 10b5-1 plan; holds 22,760 shares post-sale.

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, sold 1,974 shares (22.8K shares remaining, -8.0% vs pre-transaction holdings) at $450.00 on 2026-05-29 as part of a pre-arranged 10b5-1 trading plan. The sale was scheduled under a trading plan, not discretionary. At his prior five trades at VRTX, the 30-day and 90-day post-sale returns were negative across all five instances (ranging from -2.6% to -9.8%), though current price of $425.09 sits -16.3% from the 52-week high. Vertex's fundamentals remain solid with $3.0B in revenue, net income of $1.0B, annual revenue growth of +8.9%, and a market cap of $107.9B.

EVP Carmen Bozic sold 1,354 shares of VRTX at $453.45 under 10b5-1 plan; stock now $434.31, down 14.5% from 52-week high of $507.92.

Carmen Bozic, EVP and CMO, sold 1,354 shares at $453.45 on 2026-05-15 as part of a pre-arranged 10b5-1 trading plan, reducing holdings by -5.2% to 24,734 shares. The current price of $434.31 is down 14.5% from the 52-week high of $507.92, and the stock has declined 1.6% over 30 days and 7.6% over 90 days. Across his prior VRTX trades, Bozic's recent 2026 sales have shown 30-day returns of -4.6%, -9.4%, and -9.8%, while his two 2024 sales at this ticker showed 30-day returns of -1.8% and -1.5%. The scheduled nature of this sale under a 10b5-1 plan indicates predetermined execution rather than discretionary positioning.

EVP/CMO Bozic Carmen sold 6,988 shares of VRTX at $450.00; scheduled 10b5-1 plan, strong track record (66.67% well-timed rate).

Carmen Bozic, EVP and CMO, disposed of 6,988 shares at $450.00 totaling $3,144,600.00 under a pre-arranged 10b5-1 trading plan, meaning this was scheduled execution rather than discretionary conviction. While the sale reduces her holdings from a reported post-transaction level of 26,088 shares, her track record on prior sells shows a 66.67% well-timed rate with an avg 90d return of -1.2%, suggesting her dispositions have historically preceded modest declines. The stock is currently -11.3% from its 52-week high of $507.92 and down -8.4% over 90 days, indicating recent weakness that aligns with her historical patterns. Given the structured nature of the plan and the moderate position retention (26,088 shares remaining), this transaction reflects programmatic portfolio management rather than a bearish strategic signal, though the well-timed historical pattern warrants monitoring.

Bozic (EVP/CMO) sold 2,329 shares of VRTX at $450.95 on 2026-03-27; stock now $446.54, off -12.4% from 52-week high.

Bozic sold 2,329 shares for $1,050,262.55 on 2026-03-27, reducing holdings by 6.6% to 33,076 shares remaining. The sale occurred just two weeks before VRTX's current price of $446.54, a decline of approximately -1.0% from the sale price, and the stock is now -12.4% below its 52-week high of $509.50. Across his 14 prior open-market sells at all tickers, Bozic has achieved a 66.67% well-timed rate at the 90-day mark, though his same-ticker history at VRTX shows 2 of 3 measurable 90-day outcomes were well-timed (sales before declines). The fundamentals remain solid: VRTX posted $3.1B quarterly revenue (+8.9% annual growth) and $1.1B net income, trading at a P/E of 13.89 on a $113.4B market cap. The sale reflects an executive disposition of a modest portion of holdings during a period of stock price pressure, without disclosed material context.

EVP Carmen Bozic sold 2,329 shares of VRTX at $481.79; stock now down 10.0% from 52-week high

Carmen Bozic, EVP and CMO at Vertex Pharmaceuticals, sold 2,329 shares at $481.79 on 2026-03-13, reducing holdings from 37,734 to 35,405 shares. The current stock price of $462.49 reflects a -10.0% decline from the 52-week high of $513.76, and the sale executed near the peak of the trading range. Examining his prior VRTX transactions, three of four prior sells achieved negative 90-day returns (well-timed): -2.8%, -5.8%, and -1.8%, indicating a consistent pattern of selling ahead of downturns at this specific ticker. The broader company fundamentals remain solid with $3.1B quarterly revenue, 8.9% annual growth, and a P/E of 14.39, so this sale does not signal fundamental deterioration but rather reflects an established selling pattern that has aligned with subsequent price weakness.

EVP McKechnie Duncan sells 2,633 VRTX shares at $498.42; third sale in 7 days, post-transaction holdings drop to 12,489 shares

McKechnie Duncan, Chief Commercial Officer, executed the third consecutive open-market sale of VERTEX PHARMACEUTICALS stock within seven days (prior sales on 2026-03-04 and 2026-02-25), selling 2,633 shares at $498.42 on 2026-03-11 for $1,312,339.86. His post-transaction holdings fell to 12,489 shares, representing a 17.4% reduction from the 15,122 shares he held before this sale. The recurring pattern of sales at prices significantly above the current market price of $469.34 (the transaction prices were 6.2% above current) is noteworthy, though no measurable outcomes from the prior sales are yet available. With a strong fundamental backdrop (net income of $1,082,900,000.00 on revenue of $3,076,400,000.00 and a P/E ratio of 14.60), the timing and sequence of these concentrated dispositions merit observation by investors tracking executive positioning.

EVP McKechnie Duncan sold 2,437 shares of VRTX at $475.30, reducing holdings 13.9% to 15,122 shares; stock now -11.1% from 52-week high.

McKechnie Duncan, EVP and Chief Commercial Officer, sold 2,437 shares on 2026-03-04 at $475.30, totaling $1,158,306.10. The sale reduced his holdings from 17,559 to 15,122 shares, a 13.9% reduction. The trade occurred as VRTX stock trades $456.69, currently -11.1% from its 52-week high of $513.76, suggesting the insider sold near recent peaks. His prior sell activity at VRTX (two sales on 2026-02-25) is still within their measurement windows with outcomes not yet measurable. The company's fundamentals remain solid with $3.1B quarterly revenue, $1.1B net income, and positive annual growth of 8.9%, alongside a reasonable P/E of 14.21. The open-market sale itself—a material reduction in stake by a senior commercial officer—is a discrete event that warrants tracking, particularly as it follows closely on other recent VRTX sells by this insider.

EVP Carmen Bozic sold 2,329 shares of VRTX at $480.31 on 2026-02-27 for $1,118,641.99; stock now $474.27, near 52-week highs.

Carmen Bozic, EVP and CMO, sold 2.3K shares at $480.31, reducing holdings by 5.8% to 37.7K shares. The sale price was near the 52-week high of $513.76, and the current price of $474.27 is -7.7% from that peak. At VRTX specifically, Bozic's prior 5 trades show 4 of 5 were well-timed at the 90-day mark, with 3 of 5 resulting in negative 90-day returns after the sale; this pattern suggests an ability to execute around inflection points. VRTX trades at a P/E of 14.76 with $3.1B quarterly revenue and +8.9% annual growth, indicating a mature, profitable franchise where insider sales around elevated valuations may reflect rational capital allocation rather than distress signals.